NeoGenomics, Inc. Investment Income, Interest
NeoGenomics, Inc. (NEO) reported Investment Income, Interest of $1.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-07-28
- NeoGenomics, Inc. investment income, interest for the quarter ending 2026-06-30 was $1.21M, a 46.35% decline year-over-year.
- NeoGenomics, Inc. investment income, interest for the quarter ending 2026-03-31 was $1.27M, a 65.79% decline year-over-year.
- NeoGenomics, Inc. investment income, interest for the quarter ending 2025-12-31 was $1.52M, a 64.81% decline year-over-year.
- NeoGenomics, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.56M, a 66.55% decline year-over-year.
- NeoGenomics, Inc. investment income, interest for fiscal 2025 was $9.07M, a 50.78% decline from fiscal 2024.
- NeoGenomics, Inc. investment income, interest for fiscal 2024 was $18.43M, a 9.02% increase from fiscal 2023.
- NeoGenomics, Inc. investment income, interest for fiscal 2023 was $16.90M, a 178.22% increase from fiscal 2022.
- NeoGenomics, Inc. investment income, interest for fiscal 2022 was $6.08M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M 10-Q · filed 2026-07-28 | $2.49M 10-Q · filed 2026-07-28 | $4.01M derived: sum of 3 quarters · filed 2026-07-28 | $5.57M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $1.27M 10-Q · filed 2026-04-28 | $2.80M derived: sum of 2 quarters · filed 2026-04-28 | $4.36M derived: sum of 3 quarters · filed 2026-04-28 | $6.62M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.09M derived: sum of 2 quarters · filed 2026-02-17 | $5.35M derived: sum of 3 quarters · filed 2026-07-28 | $9.07M 10-K · filed 2026-02-17 |
| 2025-09-30 | $1.56M 10-Q · filed 2025-10-28 | $3.83M derived: sum of 2 quarters · filed 2026-07-28 | $7.55M 10-Q · filed 2025-10-28 | $11.88M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $2.26M 10-Q · filed 2026-07-28 | $5.98M 10-Q · filed 2026-07-28 | $10.31M derived: sum of 3 quarters · filed 2026-07-28 | $14.98M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $3.72M 10-Q · filed 2026-04-28 | $8.05M derived: sum of 2 quarters · filed 2026-04-28 | $12.72M derived: sum of 3 quarters · filed 2026-04-28 | $17.31M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $9.00M derived: sum of 2 quarters · filed 2026-02-17 | $13.59M derived: sum of 3 quarters · filed 2026-02-17 | $18.43M 10-K · filed 2026-02-17 |
| 2024-09-30 | $4.67M 10-Q · filed 2025-10-28 | $9.27M derived: sum of 2 quarters · filed 2025-10-28 | $14.10M 10-Q · filed 2025-10-28 | $18.94M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $4.59M 10-Q · filed 2025-07-29 | $9.43M 10-Q · filed 2025-07-29 | $14.27M derived: sum of 3 quarters · filed 2026-02-17 | $18.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $4.83M 10-Q · filed 2025-04-29 | $9.68M derived: sum of 2 quarters · filed 2026-02-17 | $14.20M derived: sum of 3 quarters · filed 2026-02-17 | $18.51M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $9.37M derived: sum of 2 quarters · filed 2026-02-17 | $13.68M derived: sum of 3 quarters · filed 2026-02-17 | $16.90M 10-K · filed 2026-02-17 |
| 2023-09-30 | $4.53M 10-Q · filed 2024-11-05 | $8.83M derived: sum of 2 quarters · filed 2024-11-05 | $12.06M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $4.31M 10-Q · filed 2024-07-30 | $7.53M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | $6.08M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |